Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Labcyte and FIMM Announce a Collaboration Enabling “Real-Time” Science to Advance Personalized Medicine in Cancer Treatments

Published: Tuesday, January 08, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Collaboration expected to further the development of personalized medicine in cancer treatment.

Labcyte Inc. and the Institute for Molecular Medicine Finland (FIMM) are collaborating to further the development of personalized medicine in cancer treatment. Labcyte acoustic liquid handling technology has already revolutionized small-molecule research. Now, FIMM, a European leader in advanced research for new cancer therapies, will apply the technology extensively in its personalized medicine programs.

“FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”
“FIMM’s groundbreaking use of acoustic liquid handling will demonstrate the technology’s role in genetic research,” said Mark Fischer-Colbrie, CEO of Labcyte. “FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”

FIMM uses large sample sets with links to detailed patient records and genetic data to discover personalized treatment options at a faster pace.

“We see an enormous potential in expanding our use of Labcyte acoustic dispensing technology to help discover specialized leukemia treatments,” said Professor Olli Kallioniemi, director of FIMM. “This research is based on high-throughput drug sensitivity and resistance testing of leukemic cells taken from patients. This new initiative will bring us closer to the clinic and closer to patients.”

“Our aim is to find alternate treatment options for patients who simultaneously undergo treatment in the clinic,” said Kallioniemi. “We will be doing real-time science, using new scientific insights and technologies to help patients who have failed standard leukemia treatments.”

Increasing its throughput enables FIMM to do more rapid and more efficient testing. Researchers at the Institute hope to learn how leukemia cells ex-vivo respond to various types of drugs, and what the resistance mechanisms are. “Larger trials with samples from acute myeloid leukemia patients who have relapsed under standard treatment may quickly suggest individualized treatment options using existing cancer drugs,” added Kallioniemi. “We’re not saying we can cure leukemia, but for patients who have run out of options, alternative treatments may be available sooner.”

By working with FIMM to utilize acoustic liquid handling in genetics research, Labcyte will continue to expand the application of its technology in bio-marker discovery, single-cell analysis, RT-qPCR, genotyping, siRNA screening, and bio-banking.

“We are excited to be an enabling platform for improving patient care with FIMM,” said Fischer-Colbrie. “It will continue to demonstrate how acoustic liquid handling enhances life science research.”

“This research may be changing the way new and emerging drugs are introduced for patients—it is truly game-changing,” said Kallioniemi. “Labcyte technology is a key enabling platform for this drug-sensitivity testing.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Labcyte Announces Partnership with AstraZeneca
Partnership to develop new fully acoustic liquid handling system for drug screening.
Saturday, November 21, 2015
Labcyte Receives $1 Million NCI Award
The award will be used to create an innovative process to detect cancer-related proteins in samples, with initial work in breast cancer detection.
Friday, November 22, 2013
Labcyte Announces Collaboration with AstraZeneca
Companies collaborate to use acoustic dispensing combined with mass spectrometry to greatly advance drug discovery applications.
Wednesday, September 25, 2013
Moving Liquids with Sound Helps Identify Drug Candidates that Traditional Lab Techniques Miss
A paper published by the journal PLOS ONE, May 1, 2013, demonstrates that the technique used to transfer compound solutions does indeed matter.
Friday, May 03, 2013
Labcyte Inc. Closes $5.3 Million Financing
Privately-held company with products that advance acoustic liquid handling closes a Series D financing.
Thursday, January 10, 2013
Cancer Research Technology Selects the Labcyte Access™ Laboratory Workstation
Labcyte Access workstation to automate the production of assay-ready plates used in CRT's high-throughput cell based screening program
Monday, June 25, 2012
Labcyte Secures NIH Funding
The award of $196K from the National Cancer Institute will fund a collaborative cancer biomarker validation program with the Canary Center of Stanford University.
Wednesday, November 09, 2011
Labcyte Awarded 1st Patent in China
Labcyte has announced the grant of its first patent in China. Patent CN 101035681B describes how acoustic energy is used to assess the characteristics of any fluid in real time to optimize its transfer.
Thursday, September 30, 2010
Labcyte Awarded 40th US Patent
Patent number 7,717,544 describes how in real time acoustic energy is optimized to transfer a droplet of any fluid.
Wednesday, August 25, 2010
Labcyte Signs Bioscreen Instruments as Exclusive Distributor in India
Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.
Wednesday, September 23, 2009
Labcyte Awarded Second Japanese Patent
Patent covers the design for acoustics used for cell sorting and transfer.
Wednesday, August 19, 2009
Labcyte Echo Acoustic Liquid Handler an Essential Component of Pharmaceutical High-Throughput Screening
Recent issue of JBS emphasizes the importance of acoustic liquid handling in drug discovery.
Friday, August 07, 2009
Labcyte Awarded U. S. Patent Describing the Acoustic Transfer of Droplets into Small Openings Moving liquids with Sound™
The patent describes the acoustic transfer of fluid droplets into openings less than 300 microns in diameter.
Thursday, November 06, 2008
Portrait™ 630 Reagent Multi-Spotter Wins Technology Prize at MipTec 10th Anniversary Conference
The European Laboratory Robotics Interest Group has selected the Labcyte Portrait 630 reagent multi-spotter as the winner of its annual Technology Prize.
Tuesday, May 22, 2007
Labcyte Awarded 28th US Patent Describing Improved HTS Microplates
The US Patent 7,185, 969 describes microplates used in high-throughput screening that have low electrical resistance.
Thursday, March 15, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos